Demand for primate studies, crucial for drug safety testing, has surged in China due to the rapid growth of biologics and next-generation therapies. Prices for lab monkeys have doubled within a year, complicating drug development and leading to increased imports from neighboring countries. The situation echoes the shortages experienced during the COVID-19 pandemic and reflects China’s emergence as a key player in global pharmaceutical innovation, now accounting for a significant portion of the world’s drug pipeline. As a result, companies face longer planning timelines for studies, potentially delaying the approval of new treatments amidst ongoing competition for limited resources.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.businesstimes.com.sg/international/lab-monkeys-us26000-show-chinas-biotech-quest-rival-us
